指南与共识泌尿生殖MR

PI-RADS委员会关于疑似前列腺癌未活检男性无对比剂MRI的立场:叙述性综述

PI-RADS Committee Position on MRI Without Contrast Medium in Biopsy-Naive Men With Suspected Prostate Cancer: Narrative Review.
PubMed 文献 · AJR Am J Roentgenol · 2020-11-19

本文为PI-RADS委员会的叙述性综述,讨论在疑似前列腺癌未活检男性中采用无钆对比剂的双参数MRI的可行性。委员会提出需满足高质量成像、专家判读和患者召回或台上监测等前提,并指出需前瞻性研究按无增强MRI制定活检决策后,才能给出循证推荐。

要点

  • 无对比剂双参数MRI仅可在高质量成像、专家判读与患者召回或台上监测等前提满足时考虑实施。
  • 按临床风险选择方案,可仅对部分未活检男性使用多参数MRI(含对比剂)。
  • 需前瞻性研究以无增强MRI决定活检,明确临床与操作获益及适用人群后方可推荐。

核心结论

  • PI-RADS委员会认为,在缺乏高质量前瞻性数据前,尚不能就无对比剂MRI作为前列腺癌初始诊断方法给出循证推荐。

研究设计与样本

  • 本文为叙述性综述,由PI-RADS委员会撰写,未报告系统检索范围与纳入文献数量。

诊断标准与关键数值

  • 双参数MRI(无钆对比剂)的实施前提包括高质量成像、专家判读质量以及患者召回或台上监测的可及性。

临床应用与阅片要点

  • 作者提出可考虑采用无钆对比剂的双参数MRI以缓解扫描仪与合格人员不足,但须以高质量成像、专家判读和患者召回或台上监测为前提。
  • 作者提出可单独或联合采用基于临床风险的方案选择,决定哪些未活检男性需要含对比剂的多参数MRI。
  • 作者指出需开展前瞻性研究,按无增强MRI制定活检决策,以界定临床与操作获益并识别可成功接受无增强扫描的患者群体。

局限性

  • 原文指出需前瞻性研究按无增强MRI制定活检决策,并明确临床与操作获益及适用人群,在获得更高质量数据前PI-RADS委员会尚不能给出循证推荐。
  • 原文提到无对比剂MRI可能带来判读者信心下降和转诊方参与度降低等风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

The steadily increasing demand for diagnostic prostate MRI has led to concerns regarding the lack of access to and the availability of qualified MRI scanners and sufficiently experienced radiologists, radiographers, and technologists to meet the demand. Solutions must enhance operational benefits without compromising diagnostic performance, quality, and delivery of service. Solutions should also mitigate risks such as decreased reader confidence and referrer engagement. One approach may be the implementation of MRI without the use gadolinium-based contrast medium (bipara-metric MRI), but only if certain prerequisites such as high-quality imaging, expert interpretation quality, and availability of patient recall or on-table monitoring are mandated. Alternatively, or in combination, a clinical risk-based approach could be used for protocol selection, specifically, which biopsy-naive men need MRI with contrast medium (multiparametric MRI). There is a need for prospective studies in which biopsy decisions are made according to MRI without contrast enhancement. Such studies must define clinical and operational benefits and identify which patient groups can be scanned successfully without contrast enhancement. These higher-quality data are needed before the Prostate Imaging Reporting and Data System (PI-RADS) Committee can make evidence-based recommendations about MRI without contrast enhancement as an initial diagnostic approach for prostate cancer workup.

来源:AJR Am J Roentgenol,查看原文。版权归原作者所有。

引用

  1. Schoots IG, Barentsz JO, Bittencourt LK, et al. PI-RADS Committee Position on MRI Without Contrast Medium in Biopsy-Naive Men With Suspected Prostate Cancer: Narrative Review. AJR Am J Roentgenol. 2020. PMID: 32812795. doi:10.2214/AJR.20.24268

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。